Pivotal Peptides modified its website to indicate 'down for maintenance' after receiving a letter from Lilly, misleadingly assuring customers via coded language for orders.
Elizabeth Gately, the agent for Pivotal Peptides, instructed customers to no longer use product names starting with 'T', instead referring to its bestseller as '11mg'.
The lawsuit from Lilly highlights serious concerns about patient safety, emphasizing that unlicensed entities should not sell untested drugs to consumers.
Lilly's legal actions against companies like Pivotal Peptides come following the FDA's actions regarding compounded versions of tirzepatide amid a drug shortage situation.
Collection
[
|
...
]